CATX

0.74335.19%
MK

Michael K. Schultz

Co-Founder & Senior Scientific Advisor

Dr. Michael K. Schultz, PhD, has been Chief Science Officer at Perspective Therapeutics, Inc. since July 2026. Dr. Schultz is the Co-Founder, Chief Science Officer and Director at Viewpoint Molecular Targeting, Inc. and serves as its Secretary. He is a founding Member and Chief Science Officer of Viewpoint Molecular Targeting, Inc. Dr. Schultz is concurrently an Associate Professor of Radiology and Free Radical and Radiation Biology at the University of Iowa. Dr. Schultz has held continuous funding for over a decade from the National Institutes of Health (NIH)/ National Cancer Institute (NCI) and has published over 75 peer-reviewed journal articles, book chapters and invited publications. Dr. Schultz is a Principal Investigator on a currently funded NIH Research Project Grant (R01) to conduct a Phase 1 clinical imaging and therapy trial of VMT-a-NET at the University of Iowa and has served as Co-Investigator on Small Business Innovation Research grant projects. Dr. Schultz is a Project Leader for the University of Iowa NIH sponsored Specialized Project of Research Excellence in Neuroendocrine Tumors and has been the primary architect, Principal Investigator, or Co-Investigator in total of grants from the NIH, Nuclear Regulatory Commission, Department of Energy, Department of Homeland Security and industry funded research projects. Dr. Schultz has of experience in product management in radiation detectors, electronics and software (PerkinElmer/Ametec); in radiopharmaceutical CMC/IND approvals; and served as a consultant to Algeta ASA (acquired by Bayer) on the CMC for the first alpha-particle targeted therapy approved in the United States (Xofigo).

Positions